Clinical Trials Browser

Carcinoma, Ovarian Epithelial, Adnexal Diseases, Carcinoma, Genital Diseases, Female, Genital Neoplasms, Female, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms, Urogenital Neoplasms

NCT04316351 2020-07-23

Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib Resistance

Phase 2 Unknown

60 enrolled

Thoracic

IIIb/IV NSCLC With T790M Positive Mutations Failed to Osimertinib Therapy

NCT04207463 2020-06-17

A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors

Phase 2 Unknown

150 enrolled

EndocrineGastrointestinalNET

Digestive System Neoplasms, Neuroendocrine Tumors

NCT04363255 2020-04-28

First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC

Phase 2 Unknown

20 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT04358562 2020-04-24

Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib

Phase 2 Unknown

240 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04080154 2020-04-03

ALTER-H-002

Phase 2 Unknown

28 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT04314297 2020-03-19

Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study

Phase 2 Unknown

33 enrolled

Thoracic

Small Cell Lung Carcinoma

Clinical Trials

Clinical Trial of Eribulin in Combination with Anrotinib for HER-2 Negative Locally Advanced or Metastatic Breast Cancer

TAS-102 and Anlotinib in ≥3 Lines mGC

NeoATCT

Hypofractionated Stereotactic Radiotherapy With Anlotinib in Patients With Recurrent High-Grade Gliomas

SAVE

ALTER-GO-020

ALTER-G-001

FAITH

Anlotinib Maintenance Treatment for Advanced Soft Tissue Sarcoma

A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL

Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)

Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma

Anlotinib Plus PD-1 Inhibitor as 2nd-line Threapy in Patients With Metastatic Pancreatic Cancer

FOCUS-A

PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer

Anlotinib and Radiotherapy in Resectable Soft Tissue Sarcoma

ACNTBC

Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)

Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation

Niraparib Plus Anlotinib for Recurrent Ovarian Cancer

Alotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer

Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer

ALTER-C003

Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer

AK105 Combined With Anlotinib in Patients With Cervical Cancer

EASOAIPPGL

Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma

Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma

Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC

Study of Pembrolizumab Combined With Anlotinib in the First Line Therapy for R/M HNSCC With CPS≥1

Camrelizumab Plus Amlotinib and Chemotherapy in the First-line Treatment of Melanoma

ADCb (Anlotinib/Docetaxel/Carboplatin) as Neoadjuvant Therapy for Triple-Negative Breast Cancer

the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer

Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer

Fulvestrant Plus Anlotinib in HR(+)/HER2(-) Metastatic Breast Cancer With FGFR Mutation

Anlotinib Neoadjuvant Treatment in Locally Advanced Thyroid Cancer

A Study of Anlotinib in the Treatment of Recurrent High-grade Glioma

SHR-1210 in Combination With Anlotinib in Patients With Advanced or Metastatic Esophageal Squamous Cell Cancer

Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer

Pegylated Liposomal Doxorubicin Combined With Anlotinib for Neoadjuvant Treatment of Soft Tissue Sarcoma

Anlotinib to Malignant Brainstem Glioma

ANNIE

Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy

ANLOLA

Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib Resistance

A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors

First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC

Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib

ALTER-H-002

Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study